{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:29:57Z","timestamp":1779316197912,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"crossref","award":["10.13039\/100004312"],"award-info":[{"award-number":["10.13039\/100004312"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1093\/annonc\/mdy461","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T21:45:01Z","timestamp":1539812701000},"page":"124-131","source":"Crossref","is-referenced-by-count":57,"title":["Biomarker analysis beyond angiogenesis: RAS\/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE\u2014a global phase III study"],"prefix":"10.1016","volume":"30","author":[{"given":"T.","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C.","family":"Portnoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Obermannov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bodoky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Prausov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garcia-Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Garc\u00eda-Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Grothey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.","family":"Wijayawardana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.R.","family":"Hozak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nasroulah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1093\/annonc\/mdy461_bb0010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy461_bb0015","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy461_bb0020","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/annonc\/mdx767","article-title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study","volume":"29","author":"Tabernero","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy461_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2017.03.007","article-title":"Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial","volume":"78","author":"Yoshino","year":"2017","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdy461_bb0030","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/annonc\/mdw402","article-title":"Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression","volume":"27","author":"Obermannov\u00e1","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy461_bb0035","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy461_bb0040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejso.2014.11.001","article-title":"Is right-side colon cancer different to left-side colorectal cancer? A systematic review","volume":"41","author":"Lee","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy461_bb0045","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO.2016.34.15_suppl.3505","article-title":"The relationship between primary tumor sidedness and prognosis in colorectal cancer","volume":"34","author":"Schrag","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy461_bb0050","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1093\/annonc\/mdy461_bb0055","doi-asserted-by":"crossref","first-page":"9732","DOI":"10.3748\/wjg.v20.i29.9732","article-title":"Beyond KRAS: predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer","volume":"20","author":"De Stefano","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1093\/annonc\/mdy461_bb0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1470-2045(13)70163-3","article-title":"Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO)","volume":"14","author":"Seymour","year":"2013","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1093\/annonc\/mdy461_bb0065","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy461_bb0070","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.35.15_suppl.3538","article-title":"Velour trial biomarkers update: impact of RAS, BRAF, and sidedness on aflibercept activity","volume":"35","author":"Wirapati","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy461_bb0075","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer retrospective analyses of the CRYSTAL and FIRE-3 trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdy461_bb0080","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdy461_bb0085","doi-asserted-by":"crossref","first-page":"dju427","DOI":"10.1093\/jnci\/dju427","article-title":"Primary tumor location as a prognostic factor in metastatic colorectal cancer","volume":"107","author":"Loupakis","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1093\/annonc\/mdy461_bb0090","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.clcc.2016.02.007","article-title":"Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer","volume":"15","author":"Wong","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy461_bb0095","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2017.35.15_suppl.3543","article-title":"Localization of the primary tumor and maintenance strategies after first-line oxaliplatin, fluoropyrimidine, and bevacizumab in metastatic colorectal cancer (mCRC)","volume":"35","author":"Reinacher-Schick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy461_bb0100","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/jco.2014.32.15_suppl.3600","article-title":"Gender and tumor location as predictors for efficacy: influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial","volume":"32","author":"Heinemann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy461_bb0105","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","article-title":"Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB\/SWOG 80405 (Alliance)","volume":"34","author":"Venook","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy461_bb0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6004\/jnccn.2017.0036","article-title":"Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Benson","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1093\/annonc\/mdy461_bb0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419309792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419309792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/1\/124\/27511354\/mdy461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:45:31Z","timestamp":1624697131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419309792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0923753419309792"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy461","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}